Login
Companies $CRIS
$0.42 -$0.02 (3.6%) After hours
CURIS INC logo

CURIS INC

curis.com

What Do They Do?

Develops emavusertib, an oral cancer drug candidate, for patients with lymphoma and leukemia.

How Do They Make Money?

Curis has funded operations through equity placements, license fees, milestone payments, royalties, research and development funding from collaborators, and sales of royalty rights. It no longer receives Erivedge royalties after selling the related assets and license agreement.

FY2025 revenue

Who Are Their Customers?

Genentech and Roche commercialized Erivedge under a license agreement; Curis received royalties and milestone payments. Curis sold the Erivedge assets and license agreement in November 2025.

Do Revenues Turn Into Profits?

No. It lost $7.6M in FY2025.

Operating income, FY2025
−60% of revenue
▲ +87% (Loss) vs FY2024 (−$44.5M, −408%)
Net income, FY2025
−80% of revenue
▲ +83% (Loss) vs FY2024 (−$43.4M, −398%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −5% (Loss)
vs −$7.7M in Q3 FY2025
  • Nov 2, 2026 Nasdaq issued a delisting determination over Curis's bid price Curis said it intended to request a hearing, which would stay further delisting actions.
  • Jul 24, 2026 Curis regained compliance with Nasdaq's bid-price rule Curis remained subject to a one-year discretionary panel monitor.
  • Apr 27, 2026 Nasdaq issued a delisting determination over Curis's bid price Curis said it intended to request a hearing, which would stay further delisting actions.

Shrinking. Revenue fell 11% in 4 years, from $10.6M in FY2021 to $9.4M in FY2025, about 3% a year.

Emavusertab development focus The older report described emavusertab trials in acute leukemia and lymphoma; the latest focuses on combinations for brain lymphoma and chronic lymphocytic leukemia, with acute myeloid leukemia studies substantially complete.

Erivedge royalties ended The older report described royalty and milestone income from Erivedge; the latest says Curis sold the drug-related assets and is no longer entitled to those revenues.

Who Do They Compete With?

Competes with Kurome Therapeutics, Rigel Pharmaceuticals, AstraZeneca, Hangzhou Polymed Biopharmaceuticals, Eilean Therapeutics, BeOne Medicines, AbbVie, Johnson & Johnson, Eli Lilly and, Nurix Therapeutics, Bayer, Gilead Sciences, Ono Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Jiangsu Hengrui, Novartis, Aptose Biosciences, HEC Pharma, and Ellipses Pharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support